Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2014 2
2015 3
2017 1
2018 1
2019 4
2020 2
2021 3
2022 5
2023 3
2024 5
2025 3
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Protective effect of berberine against LPS-induced injury in the intestine: a review.
Izadparast F, Riahi-Zajani B, Yarmohammadi F, Hayes AW, Karimi G. Izadparast F, et al. Cell Cycle. 2022 Nov;21(22):2365-2378. doi: 10.1080/15384101.2022.2100682. Epub 2022 Jul 19. Cell Cycle. 2022. PMID: 35852392 Free PMC article. Review.
Lipopolysaccharide (LPS; also known as endotoxin), a substance found in Gram-negative bacteria, plays a major role in sepsis and is mostly responsible for the disease's morbidity and mortality. Berberine is an isoquinoline alkaloid found in a variety of plant species that …
Lipopolysaccharide (LPS; also known as endotoxin), a substance found in Gram-negative bacteria, plays a major role in sepsis and is mostly r …
Chang-Kang-Fang alleviates diarrhea predominant irritable bowel syndrome (IBS-D) through inhibiting TLR4/NF-kappaB/NLRP3 pathway.
Zhang S, Tian D, Xia Z, Yang F, Chen Y, Yao Z, He Y, Miao X, Zhou G, Yao X, Tang J. Zhang S, et al. J Ethnopharmacol. 2024 Aug 10;330:118236. doi: 10.1016/j.jep.2024.118236. Epub 2024 Apr 24. J Ethnopharmacol. 2024. PMID: 38670405
AIM OF THE STUDY: The objective of this present investigation was to validate the efficacy of CKF on IBS-D model rats and to uncover its potential mechanism for the treatment of IBS-D. MATERIALS AND METHODS: We first established the IBS-D rat model through ne …
AIM OF THE STUDY: The objective of this present investigation was to validate the efficacy of CKF on IBS-D model rats and to uncover …
Cannabidiol-Decorated Berberine-Loaded Microemulsions Improve IBS-D Therapy Through Ketogenic Diet-Induced Cannabidiol Receptors Overexpression.
Fan X, Shi J, Liu Y, Zhang M, Lu M, Qu D. Fan X, et al. Int J Nanomedicine. 2023 May 30;18:2839-2853. doi: 10.2147/IJN.S402871. eCollection 2023. Int J Nanomedicine. 2023. PMID: 37273286 Free PMC article.
BACKGROUND: Berberine (BR) shows promise as a candidate for treating irritable bowel syndrome with diarrhea (IBS-D). ...Moreover, the treatment with CBD/BR-MEs and KD not only blocked the CREB/BDNF/c-Fos signaling in the brain but also decreased the levels of neurot …
BACKGROUND: Berberine (BR) shows promise as a candidate for treating irritable bowel syndrome with diarrhea (IBS-D). ...Moreov …
Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice.
Hou Q, Zhu S, Zhang C, Huang Y, Guo Y, Li P, Chen X, Wen Y, Han Q, Liu F. Hou Q, et al. Biomed Pharmacother. 2019 Oct;118:109206. doi: 10.1016/j.biopha.2019.109206. Epub 2019 Jul 12. Biomed Pharmacother. 2019. PMID: 31306972 Free article.
C57BL/6 wild type (WT) and A20 IEC-KO mice (48 each) were randomly divided into normal control (NC), model control (MC), rifaximin and berberine groups (12 mice per group). An experimental model of IBS-D was established using 4% acetic acid and evaluated by haematox …
C57BL/6 wild type (WT) and A20 IEC-KO mice (48 each) were randomly divided into normal control (NC), model control (MC), rifaximin and be …
The Possible Synergistic Pharmacological Effect of an Oral Berberine (BBR) and Curcumin (CUR) Complementary Therapy Alleviates Symptoms of Irritable Bowel Syndrome (IBS): Results from a Real-Life, Routine Clinical Practice Settings-Based Study.
Wade U, Pascual-Figal DA, Rabbani F, Ernst M, Albert A, Janssens I, Dierckxsens Y, Iqtadar S, Khokhar NA, Kanwal A, Khan A. Wade U, et al. Nutrients. 2024 Apr 18;16(8):1204. doi: 10.3390/nu16081204. Nutrients. 2024. PMID: 38674895 Free PMC article.
IBS cause a significantly negative impact on quality of life (QoL). Growing pharmacological evidence suggests that berberine (BBR) and curcumin (CUR) may mitigate IBS symptoms through multiple complementary synergistic mechanisms, resulting in the attenuation …
IBS cause a significantly negative impact on quality of life (QoL). Growing pharmacological evidence suggests that berberine ( …
Berberine Enhances Intestinal Mucosal Barrier Function by Promoting Vitamin D Receptor Activity.
Huang YQ, Liu JL, Chen GX, Shen DT, Zhu W, Chen XL, Liu FB, Hou QK. Huang YQ, et al. Chin J Integr Med. 2024 Feb;30(2):143-151. doi: 10.1007/s11655-023-3547-x. Epub 2023 Apr 12. Chin J Integr Med. 2024. PMID: 37046128
RESULTS: The IBS-D rat model was successfully constructed and the symptoms were improved by berberine in a dose-dependent manner (P<0.05). ...CONCLUSION: Berberine enhances intestinal mucosal barrier function of IBS-D rats by promoting VDR activity, …
RESULTS: The IBS-D rat model was successfully constructed and the symptoms were improved by berberine in a dose-dependent mann …
Perspectives on Berberine and the Regulation of Gut Microbiota: As an Anti-Inflammatory Agent.
Jael Teresa de Jesús QV, Gálvez-Ruíz JC, Márquez Ibarra AA, Leyva-Peralta MA. Jael Teresa de Jesús QV, et al. Pharmaceuticals (Basel). 2025 Jan 31;18(2):193. doi: 10.3390/ph18020193. Pharmaceuticals (Basel). 2025. PMID: 40006007 Free PMC article. Review.
Berberine is a promising agent for modulating the intestinal microbiota, playing a crucial role in human health homeostasis. ...Berberine represents a promising adjuvant therapy for inflammatory diseases, particularly intestinal disorders, due to its multifaceted ac …
Berberine is a promising agent for modulating the intestinal microbiota, playing a crucial role in human health homeostasis. ...Be …
A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome.
Chen C, Tao C, Liu Z, Lu M, Pan Q, Zheng L, Li Q, Song Z, Fichna J. Chen C, et al. Phytother Res. 2015 Nov;29(11):1822-7. doi: 10.1002/ptr.5475. Epub 2015 Sep 24. Phytother Res. 2015. PMID: 26400188 Clinical Trial.
We aimed to evaluate clinical symptoms in diarrhea predominant irritable bowel syndrome (IBS-D) receiving berberine hydrochloride in a randomized double-blind placebo-controlled clinical trial. ...At last, berberine hydrochloride was well tolerated. So we con …
We aimed to evaluate clinical symptoms in diarrhea predominant irritable bowel syndrome (IBS-D) receiving berberine hydrochlor …
Berberine alleviates visceral hypersensitivity in rats by altering gut microbiome and suppressing spinal microglial activation.
Zhang JD, Liu J, Zhu SW, Fang Y, Wang B, Jia Q, Hao HF, Kao JY, He QH, Song LJ, Liu F, Zhu BL, Owyang C, Duan LP. Zhang JD, et al. Acta Pharmacol Sin. 2021 Nov;42(11):1821-1833. doi: 10.1038/s41401-020-00601-4. Epub 2021 Feb 8. Acta Pharmacol Sin. 2021. PMID: 33558654 Free PMC article.
Accumulating evidence shows that agents targeting gut dysbiosis are effective for improving symptoms of irritable bowel syndrome (IBS). However, the potential mechanisms remain unclear. In this study we investigated the effects of berberine on the microbiota-gut-bra …
Accumulating evidence shows that agents targeting gut dysbiosis are effective for improving symptoms of irritable bowel syndrome (IBS …
Berberine Improves Intestinal Motility and Visceral Pain in the Mouse Models Mimicking Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Symptoms in an Opioid-Receptor Dependent Manner.
Chen C, Lu M, Pan Q, Fichna J, Zheng L, Wang K, Yu Z, Li Y, Li K, Song A, Liu Z, Song Z, Kreis M. Chen C, et al. PLoS One. 2015 Dec 23;10(12):e0145556. doi: 10.1371/journal.pone.0145556. eCollection 2015. PLoS One. 2015. PMID: 26700862 Free PMC article.
CONCLUSION: Berberine significantly improved IBS-D symptoms in animal models, possibly through mu- and delta- opioid receptors. Berberine may become a new drug candidate for the successful treatment of IBS-D in clinical conditions....
CONCLUSION: Berberine significantly improved IBS-D symptoms in animal models, possibly through mu- and delta- opioid receptors …
31 results